Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan

Choon Ok Kim, Hae Wan Lee, Eun Sil Oh, Sook Jin Seong, doyoung kim, Joomi Lee, SangHoon Ahn, Young Ran Yoon, Chang Min Cho, Min Soo Park

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This study was designed to assess the pharmacokinetics (PK) and safety of fimasartan, an angiotensin II type 1 receptor blocker, in hepatic impairment patients as compared with healthy subjects. An open-label, single-dose, parallel study was conducted in 6 healthy male volunteers and 12 subjects with hepatic impairment. Healthy subjects were matched with hepatic dysfunction patients on the basis of age, gender, and body weight. After a single 120-mg oral administration of fimasartan, PK parameters and safety were analyzed between the hepatic dysfunction groups and healthy group. Compared with the healthy subjects, the geometric mean ratio and 90% confidence intervals for the maximum plasma concentration and the mean area under the plasma concentration-time curve from 0 to infinity (AUC) inf were 0.77 (0.24-2.47) and 1.11 (0.50-2.46), respectively, for the mild hepatic impairment and 6.55 (3.56-12.03) and 5.17 (4.19-6.37), respectively, for moderate hepatic impairment. However, there was no significant difference in time to peak plasma concentration (t max ) and elimination half-life, and there were no serious or severe adverse events in all subjects. Subjects with mild hepatic impairment exhibited similar bioavailability compared with healthy subjects, whereas subjects with moderate hepatic impairment seemed to exhibit a higher level of systemic exposure to fimasartan than healthy subjects. In addition, all subjects were tolerable with fimasartan.

Original languageEnglish
Pages (from-to)524-529
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume62
Issue number6
DOIs
Publication statusPublished - 2013 Dec 1

Fingerprint

Pharmacokinetics
Safety
Healthy Volunteers
Liver
Angiotensin II Type 1 Receptor Blockers
fimasartan
Biological Availability
Area Under Curve
Oral Administration
Half-Life
Body Weight
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Choon Ok ; Lee, Hae Wan ; Oh, Eun Sil ; Seong, Sook Jin ; kim, doyoung ; Lee, Joomi ; Ahn, SangHoon ; Yoon, Young Ran ; Cho, Chang Min ; Park, Min Soo. / Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan. In: Journal of Cardiovascular Pharmacology. 2013 ; Vol. 62, No. 6. pp. 524-529.
@article{86278f95d19a404c853bf4ea16dc0235,
title = "Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan",
abstract = "This study was designed to assess the pharmacokinetics (PK) and safety of fimasartan, an angiotensin II type 1 receptor blocker, in hepatic impairment patients as compared with healthy subjects. An open-label, single-dose, parallel study was conducted in 6 healthy male volunteers and 12 subjects with hepatic impairment. Healthy subjects were matched with hepatic dysfunction patients on the basis of age, gender, and body weight. After a single 120-mg oral administration of fimasartan, PK parameters and safety were analyzed between the hepatic dysfunction groups and healthy group. Compared with the healthy subjects, the geometric mean ratio and 90{\%} confidence intervals for the maximum plasma concentration and the mean area under the plasma concentration-time curve from 0 to infinity (AUC) inf were 0.77 (0.24-2.47) and 1.11 (0.50-2.46), respectively, for the mild hepatic impairment and 6.55 (3.56-12.03) and 5.17 (4.19-6.37), respectively, for moderate hepatic impairment. However, there was no significant difference in time to peak plasma concentration (t max ) and elimination half-life, and there were no serious or severe adverse events in all subjects. Subjects with mild hepatic impairment exhibited similar bioavailability compared with healthy subjects, whereas subjects with moderate hepatic impairment seemed to exhibit a higher level of systemic exposure to fimasartan than healthy subjects. In addition, all subjects were tolerable with fimasartan.",
author = "Kim, {Choon Ok} and Lee, {Hae Wan} and Oh, {Eun Sil} and Seong, {Sook Jin} and doyoung kim and Joomi Lee and SangHoon Ahn and Yoon, {Young Ran} and Cho, {Chang Min} and Park, {Min Soo}",
year = "2013",
month = "12",
day = "1",
doi = "10.1097/FJC.0000000000000010",
language = "English",
volume = "62",
pages = "524--529",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan. / Kim, Choon Ok; Lee, Hae Wan; Oh, Eun Sil; Seong, Sook Jin; kim, doyoung; Lee, Joomi; Ahn, SangHoon; Yoon, Young Ran; Cho, Chang Min; Park, Min Soo.

In: Journal of Cardiovascular Pharmacology, Vol. 62, No. 6, 01.12.2013, p. 524-529.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan

AU - Kim, Choon Ok

AU - Lee, Hae Wan

AU - Oh, Eun Sil

AU - Seong, Sook Jin

AU - kim, doyoung

AU - Lee, Joomi

AU - Ahn, SangHoon

AU - Yoon, Young Ran

AU - Cho, Chang Min

AU - Park, Min Soo

PY - 2013/12/1

Y1 - 2013/12/1

N2 - This study was designed to assess the pharmacokinetics (PK) and safety of fimasartan, an angiotensin II type 1 receptor blocker, in hepatic impairment patients as compared with healthy subjects. An open-label, single-dose, parallel study was conducted in 6 healthy male volunteers and 12 subjects with hepatic impairment. Healthy subjects were matched with hepatic dysfunction patients on the basis of age, gender, and body weight. After a single 120-mg oral administration of fimasartan, PK parameters and safety were analyzed between the hepatic dysfunction groups and healthy group. Compared with the healthy subjects, the geometric mean ratio and 90% confidence intervals for the maximum plasma concentration and the mean area under the plasma concentration-time curve from 0 to infinity (AUC) inf were 0.77 (0.24-2.47) and 1.11 (0.50-2.46), respectively, for the mild hepatic impairment and 6.55 (3.56-12.03) and 5.17 (4.19-6.37), respectively, for moderate hepatic impairment. However, there was no significant difference in time to peak plasma concentration (t max ) and elimination half-life, and there were no serious or severe adverse events in all subjects. Subjects with mild hepatic impairment exhibited similar bioavailability compared with healthy subjects, whereas subjects with moderate hepatic impairment seemed to exhibit a higher level of systemic exposure to fimasartan than healthy subjects. In addition, all subjects were tolerable with fimasartan.

AB - This study was designed to assess the pharmacokinetics (PK) and safety of fimasartan, an angiotensin II type 1 receptor blocker, in hepatic impairment patients as compared with healthy subjects. An open-label, single-dose, parallel study was conducted in 6 healthy male volunteers and 12 subjects with hepatic impairment. Healthy subjects were matched with hepatic dysfunction patients on the basis of age, gender, and body weight. After a single 120-mg oral administration of fimasartan, PK parameters and safety were analyzed between the hepatic dysfunction groups and healthy group. Compared with the healthy subjects, the geometric mean ratio and 90% confidence intervals for the maximum plasma concentration and the mean area under the plasma concentration-time curve from 0 to infinity (AUC) inf were 0.77 (0.24-2.47) and 1.11 (0.50-2.46), respectively, for the mild hepatic impairment and 6.55 (3.56-12.03) and 5.17 (4.19-6.37), respectively, for moderate hepatic impairment. However, there was no significant difference in time to peak plasma concentration (t max ) and elimination half-life, and there were no serious or severe adverse events in all subjects. Subjects with mild hepatic impairment exhibited similar bioavailability compared with healthy subjects, whereas subjects with moderate hepatic impairment seemed to exhibit a higher level of systemic exposure to fimasartan than healthy subjects. In addition, all subjects were tolerable with fimasartan.

UR - http://www.scopus.com/inward/record.url?scp=84890558682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890558682&partnerID=8YFLogxK

U2 - 10.1097/FJC.0000000000000010

DO - 10.1097/FJC.0000000000000010

M3 - Article

C2 - 24084213

AN - SCOPUS:84890558682

VL - 62

SP - 524

EP - 529

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -